{"id":"https://openalex.org/W2174392985","doi":"https://doi.org/10.1016/j.ijcard.2015.11.084","title":"Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups","display_name":"Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups","publication_year":2015,"publication_date":"2015-11-17","ids":{"openalex":"https://openalex.org/W2174392985","doi":"https://doi.org/10.1016/j.ijcard.2015.11.084","mag":"2174392985","pmid":"https://pubmed.ncbi.nlm.nih.gov/26655548"},"language":"en","primary_location":{"id":"doi:10.1016/j.ijcard.2015.11.084","doi":"https://doi.org/10.1016/j.ijcard.2015.11.084","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.ijcard.2015.11.084","pdf_url":null,"source":{"id":"https://openalex.org/S13342628","display_name":"International Journal of Cardiology","issn_l":"0167-5273","issn":["0167-5273","1874-1754"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Journal of Cardiology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5038405190","display_name":"Gregory Y.H. Lip","orcid":"https://orcid.org/0000-0002-7566-1626","observed_orcids":["https://orcid.org/0000-0002-7566-1626","https://orcid.org/0000-0002-2556-2945"]},"institutions":[{"id":"https://openalex.org/I2799802789","display_name":"Birmingham City Hospital","ror":"https://ror.org/02smq5q54","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2799630439","https://openalex.org/I2799802789"]},{"id":"https://openalex.org/I79619799","display_name":"University of Birmingham","ror":"https://ror.org/03angcq70","country_code":"GB","type":"education","lineage":["https://openalex.org/I79619799"]},{"id":"https://openalex.org/I891191580","display_name":"Aalborg University","ror":"https://ror.org/04m5j1k67","country_code":"DK","type":"education","lineage":["https://openalex.org/I891191580"]}],"countries":["DK","GB"],"is_corresponding":true,"raw_author_name":"Gregory Y.H. Lip","raw_affiliation_strings":["University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom; Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Health, Aalborg University, Aalborg, Denmark. Electronic address: g.y.h.lip@bham.ac.uk","Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Health, Aalborg University, Aalborg, Denmark","University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom; Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Health, Aalborg University, Aalborg, Denmark. Electronic address: g.y.h.lip@bham.ac.uk","institution_ids":["https://openalex.org/I79619799","https://openalex.org/I891191580"]},{"raw_affiliation_string":"Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Health, Aalborg University, Aalborg, Denmark","institution_ids":["https://openalex.org/I891191580"]},{"raw_affiliation_string":"University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom","institution_ids":["https://openalex.org/I2799802789","https://openalex.org/I79619799"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113776784","display_name":"Stephen Mitchell","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Stephen A. Mitchell","raw_affiliation_strings":["DRG Abacus, Bicester, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"DRG Abacus, Bicester, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090463130","display_name":"Xianchen Liu","orcid":"https://orcid.org/0000-0003-0411-1050","observed_orcids":["https://orcid.org/0000-0003-0411-1050","https://orcid.org/0000-0002-4325-2545"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Xianchen Liu","raw_affiliation_strings":["Global Health and Value, Pfizer Inc., New York, NY, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Health and Value, Pfizer Inc., New York, NY, United States","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045558489","display_name":"Larry Z. Liu","orcid":"https://orcid.org/0009-0006-3883-8134","observed_orcids":["https://orcid.org/0009-0006-3883-8134"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]},{"id":"https://openalex.org/I205783295","display_name":"Cornell University","ror":"https://ror.org/05bnh6r87","country_code":"US","type":"education","lineage":["https://openalex.org/I205783295"]},{"id":"https://openalex.org/I4387153466","display_name":"Weill Cornell Medicine","ror":"https://ror.org/02r109517","country_code":"US","type":"education","lineage":["https://openalex.org/I205783295","https://openalex.org/I4387153466"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Larry Z. Liu","raw_affiliation_strings":["Global Health and Value, Pfizer Inc., New York, NY, United States; Weill Medical College, Cornell University, New York, NY, United States","Global Health and Value, Pfizer Inc., New York, NY, United States","Weill Medical College, Cornell University, New York, NY, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Health and Value, Pfizer Inc., New York, NY, United States; Weill Medical College, Cornell University, New York, NY, United States","institution_ids":["https://openalex.org/I180857899","https://openalex.org/I205783295","https://openalex.org/I4387153466"]},{"raw_affiliation_string":"Global Health and Value, Pfizer Inc., New York, NY, United States","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Weill Medical College, Cornell University, New York, NY, United States","institution_ids":["https://openalex.org/I205783295","https://openalex.org/I4387153466"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110208931","display_name":"Hemant M. Phatak","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hemant Phatak","raw_affiliation_strings":["BMS, Princeton, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BMS, Princeton, United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068436236","display_name":"Sumesh Kachroo","orcid":"https://orcid.org/0000-0002-7190-6323","observed_orcids":["https://orcid.org/0000-0002-7190-6323"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sumesh Kachroo","raw_affiliation_strings":["BMS, Princeton, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BMS, Princeton, United States","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5030327324","display_name":"Sarah Batson","orcid":"https://orcid.org/0009-0006-4062-5648","observed_orcids":["https://orcid.org/0009-0006-4062-5648"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sarah Batson","raw_affiliation_strings":["DRG Abacus, Bicester, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"DRG Abacus, Bicester, United Kingdom","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":6,"corresponding_author_ids":["https://openalex.org/A5038405190"],"corresponding_institution_ids":["https://openalex.org/I2799802789","https://openalex.org/I79619799","https://openalex.org/I891191580"],"apc_list":{"value":3970,"currency":"USD","value_usd":3970},"apc_paid":null,"fwci":9.1802,"has_fulltext":false,"cited_by_count":89,"citation_normalized_percentile":{"value":0.9852847,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":95,"max":100},"biblio":{"volume":"204","issue":null,"first_page":"88","last_page":"94"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10065","display_name":"Atrial Fibrillation Management and Outcomes","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10065","display_name":"Atrial Fibrillation Management and Outcomes","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10285","display_name":"Venous Thromboembolism Diagnosis and Management","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2724","display_name":"Internal Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10227","display_name":"Acute Ischemic Stroke Management","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/direct-oral-anticoagulants","display_name":"direct oral anticoagulants","score":0.984000027179718},{"id":"https://openalex.org/keywords/non-valvular-atrial-fibrillation","display_name":"non-valvular atrial fibrillation","score":0.9929999709129333},{"id":"https://openalex.org/keywords/apixaban","display_name":"apixaban","score":0.8370000123977661},{"id":"https://openalex.org/keywords/dabigatran","display_name":"dabigatran","score":1.0},{"id":"https://openalex.org/keywords/rivaroxaban","display_name":"rivaroxaban","score":1.0},{"id":"https://openalex.org/keywords/edoxaban","display_name":"edoxaban","score":1.0},{"id":"https://openalex.org/keywords/stroke-prevention","display_name":"stroke prevention","score":0.859000027179718},{"id":"https://openalex.org/keywords/systemic-embolism","display_name":"systemic embolism","score":0.9179999828338623},{"id":"https://openalex.org/keywords/major-bleeding","display_name":"major bleeding","score":0.8489999771118164},{"id":"https://openalex.org/keywords/chads2-score","display_name":"CHADS2 score","score":0.9430000185966492},{"id":"https://openalex.org/keywords/secondary-stroke-prevention","display_name":"secondary stroke prevention","score":0.9179999828338623},{"id":"https://openalex.org/keywords/warfarin-comparison","display_name":"warfarin comparison","score":0.8550000190734863},{"id":"https://openalex.org/keywords/anticoagulation-management","display_name":"anticoagulation management","score":0.8069999814033508}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.984387993812561},{"id":"https://openalex.org/C2778810321","wikidata":"https://www.wikidata.org/wiki/Q419345","display_name":"Dabigatran","level":4,"score":0.9580749273300171},{"id":"https://openalex.org/C2780290652","wikidata":"https://www.wikidata.org/wiki/Q21011234","display_name":"Edoxaban","level":5,"score":0.9580622911453247},{"id":"https://openalex.org/C2778661090","wikidata":"https://www.wikidata.org/wiki/Q420262","display_name":"Rivaroxaban","level":4,"score":0.940662145614624},{"id":"https://openalex.org/C2780638905","wikidata":"https://www.wikidata.org/wiki/Q414462","display_name":"Apixaban","level":5,"score":0.9234163761138916},{"id":"https://openalex.org/C2779161974","wikidata":"https://www.wikidata.org/wiki/Q815819","display_name":"Atrial fibrillation","level":2,"score":0.7759671211242676},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5443011522293091},{"id":"https://openalex.org/C164705383","wikidata":"https://www.wikidata.org/wiki/Q10379","display_name":"Cardiology","level":1,"score":0.43449974060058594},{"id":"https://openalex.org/C95190672","wikidata":"https://www.wikidata.org/wiki/Q815382","display_name":"Meta-analysis","level":2,"score":0.41602838039398193},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.3367496728897095},{"id":"https://openalex.org/C2776301958","wikidata":"https://www.wikidata.org/wiki/Q407431","display_name":"Warfarin","level":3,"score":0.23145881295204163}],"mesh":[{"descriptor_ui":"D000069552","descriptor_name":"Rivaroxaban","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000069552","descriptor_name":"Rivaroxaban","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000069604","descriptor_name":"Dabigatran","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000069604","descriptor_name":"Dabigatran","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000925","descriptor_name":"Anticoagulants","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000925","descriptor_name":"Anticoagulants","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D001281","descriptor_name":"Atrial Fibrillation","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":false},{"descriptor_ui":"D001281","descriptor_name":"Atrial Fibrillation","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001281","descriptor_name":"Atrial Fibrillation","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D006470","descriptor_name":"Hemorrhage","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011720","descriptor_name":"Pyrazoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D011720","descriptor_name":"Pyrazoles","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011728","descriptor_name":"Pyridones","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D011728","descriptor_name":"Pyridones","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D013844","descriptor_name":"Thiazoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D013844","descriptor_name":"Thiazoles","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D014812","descriptor_name":"Vitamin K","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016032","descriptor_name":"Randomized Controlled Trials as Topic","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D017326","descriptor_name":"Clinical Trials, Phase III as Topic","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1016/j.ijcard.2015.11.084","doi":"https://doi.org/10.1016/j.ijcard.2015.11.084","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.ijcard.2015.11.084","pdf_url":null,"source":{"id":"https://openalex.org/S13342628","display_name":"International Journal of Cardiology","issn_l":"0167-5273","issn":["0167-5273","1874-1754"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Journal of Cardiology","raw_type":"journal-article"},{"id":"pmid:26655548","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/26655548","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International journal of cardiology","raw_type":"Comparative Study"},{"id":"pmh:oai:pure.atira.dk:publications/cb43e51a-a7e3-406b-9ef9-bd84dc6f7a26","doi":null,"is_oa":false,"landing_page_url":"https://vbn.aau.dk/da/publications/cb43e51a-a7e3-406b-9ef9-bd84dc6f7a26","pdf_url":null,"source":{"id":"https://openalex.org/S4306401731","display_name":"VBN Forskningsportal (Aalborg Universitet)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I891191580","host_organization_name":"Aalborg University","host_organization_lineage":["https://openalex.org/I891191580"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Lip, G Y H, Mitchell, S A, Liu, X, Liu, L Z, Phatak, H, Kachroo, S & Batson, S 2016, 'Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation : Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups', International Journal of Cardiology, vol. 204, pp. 88-94. https://doi.org/10.1016/j.ijcard.2015.11.084","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/systematic-review","display_name":"Systematic Review"},{"id":"https://openalex.org/study-designs/meta-analysis","display_name":"Meta-Analysis"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":63,"referenced_works":["https://openalex.org/W28302531","https://openalex.org/W189017593","https://openalex.org/W198550484","https://openalex.org/W1491439999","https://openalex.org/W1504183466","https://openalex.org/W1919258584","https://openalex.org/W1967404521","https://openalex.org/W1972142091","https://openalex.org/W1977849235","https://openalex.org/W1979180382","https://openalex.org/W1982179895","https://openalex.org/W1985700561","https://openalex.org/W1987516119","https://openalex.org/W2005947177","https://openalex.org/W2010152642","https://openalex.org/W2011932878","https://openalex.org/W2013896089","https://openalex.org/W2020148377","https://openalex.org/W2023143117","https://openalex.org/W2031717872","https://openalex.org/W2033102959","https://openalex.org/W2035626182","https://openalex.org/W2036833818","https://openalex.org/W2049384831","https://openalex.org/W2054152757","https://openalex.org/W2057773101","https://openalex.org/W2071405148","https://openalex.org/W2083426277","https://openalex.org/W2092923655","https://openalex.org/W2093223772","https://openalex.org/W2096246254","https://openalex.org/W2097156473","https://openalex.org/W2097854437","https://openalex.org/W2101909990","https://openalex.org/W2105027557","https://openalex.org/W2108745446","https://openalex.org/W2110258159","https://openalex.org/W2113021651","https://openalex.org/W2114775432","https://openalex.org/W2116384196","https://openalex.org/W2118243040","https://openalex.org/W2130047524","https://openalex.org/W2131214033","https://openalex.org/W2131854220","https://openalex.org/W2136489990","https://openalex.org/W2138868169","https://openalex.org/W2143034000","https://openalex.org/W2150264762","https://openalex.org/W2152623033","https://openalex.org/W2156558996","https://openalex.org/W2157459435","https://openalex.org/W2160643867","https://openalex.org/W2162508946","https://openalex.org/W2162720940","https://openalex.org/W2164168324","https://openalex.org/W2169997396","https://openalex.org/W2170350621","https://openalex.org/W2202544074","https://openalex.org/W2416255579","https://openalex.org/W2598936606","https://openalex.org/W4229847571","https://openalex.org/W6658412489","https://openalex.org/W6929062034"],"related_works":["https://openalex.org/W6939916574","https://openalex.org/W2888947027","https://openalex.org/W2523933248","https://openalex.org/W4293462369","https://openalex.org/W2806769225","https://openalex.org/W1987516119","https://openalex.org/W3047121595","https://openalex.org/W1736100602","https://openalex.org/W2981502991","https://openalex.org/W2579460460"],"abstract_inverted_index":null,"counts_by_year":[{"year":2026,"cited_by_count":5},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":5},{"year":2021,"cited_by_count":8},{"year":2020,"cited_by_count":11},{"year":2019,"cited_by_count":10},{"year":2018,"cited_by_count":13},{"year":2017,"cited_by_count":17},{"year":2016,"cited_by_count":10}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}